COLL, US19459J1043

Oppenheimer starts coverage of Collegium Pharmaceutical stock

Published on 10/06/2026 at 04:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 199.9 million, up 6.00 percent year over year. For Collegium Pharmaceutical stock, 2026 guidance is USD 825-855 million.

COLL, US19459J1043, Illustration mit AI erstellt.

Collegium Pharmaceutical (ISIN US19459J1043) became the subject of Oppenheimer coverage on September 23, 2026, when the brokerage assigned an Outperform rating and a USD 50.00 price target, according to Nasdaq. The call puts the specialty pharmaceutical company in a broader transition from pain medicines toward central nervous system products.

Oppenheimer sees a broader portfolio

The September 23, 2026 analyst action followed Collegium's acquisition-led expansion in attention deficit hyperactivity disorder treatments. The company added Azstarys to its portfolio and is developing a larger commercial platform alongside Jornay PM, while its established pain business continues to generate cash.

For the second quarter of 2026, total net product revenue reached USD 199.9 million, up 6.00 percent from the same quarter of 2025, according to Benzinga. Jornay PM contributed USD 46.1 million, with revenue up 41.00 percent year over year.

Guidance shows growth and pressure

Management's full-year 2026 product revenue guidance is USD 825 million to USD 855 million, a range that represents an 8.00 percent increase at the midpoint compared with 2025. The outlook also includes USD 190 million to USD 200 million for Jornay PM and USD 65 million to USD 75 million for Azstarys.

The guidance combines growth in the ADHD portfolio with pressure in the pain franchise. Second-quarter Nucynta franchise revenue fell 24.00 percent year over year to USD 35.2 million because of lower net pricing for authorized generic products, while Belbuca revenue rose 10.00 percent to USD 57.7 million. Adjusted earnings before interest, taxes, depreciation and amortization reached USD 113.8 million in the second quarter, up 8.00 percent year over year.

Stock context and investor reference

On October 5, 2026, Collegium had a market capitalization of USD 709.3 million and a 52-week range of USD 21.43 to USD 50.79. Nasdaq is the primary exchange, and the company operates in the Healthcare sector and specialty and generic drug manufacturing.

Lang & Schwarz showed a prior close of EUR 19.50 on October 2, 2026. The data carried no current October 6 quotation, so the prior close is the relevant euro market reference here; it is separate from the USD analyst target and primary-exchange context.